Psoriasis Drugs Poised For The Q2 Spotlight
With Celgene's psoriasis pill Otezla for sale and AbbVie in the midst of launching a new competitor to blockbuster brands like Novartis' Cosentyx and J&J's Tremfya, investors will be focused on the category as drug makers report second quarter financials.
You may also be interested in...
Belgium-headquartered UCB has a group of antibody-based products in mid to late-stage clinical studies which will be competing in the dermatology/immune disorders marketplace in the next few years.
A 6% negative pricing impact in the US and generic Zytiga were headwinds for Johnson & Johnson's pharmaceutical business in the second quarter.
Spark signaled in an SEC filing that its merger with Roche could be delayed into 2020, fueling more speculation that FTC is increasing scrutiny over biopharma mergers.